Journals / Dicle Tıp Dergisi / 2019 / Cilt: 46 - Sayı: 4

The importance of clinical and pathological features in bladder cancer and its effects on disease course

Mesane kanserinde klinik ve patolojik özelliklerin önemi ve hastalık seyrine etkisi

Pages
821–829
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was asignificant difference between the overall survival rates of group 1 and group 2(p=0.02).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Bladder cancer (BC) is the most common malignancy of the urinary system and the incidence of BC variesregionally.
📊
Key Findings & Data:Thesurvival rates of the patients were calculated for diverse clinical and pathological findings.Results:In a total of 124 patients, 23 (18.5%) of patients were female and 101(81.5%) of patients were male, themedian age of all patients was 64 (IQR: 21-92).
💡
Conclusion & Impact:There was asignificant difference between the overall survival rates of group 1 and group 2(p=0.02).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Bladder cancer (BC) is the most common malignancy of the urinary system and the incidence of BC variesregionally. Bladder cancer is more common in men than in women. Tumor stage and grade are the most importantprognostic factors of BC. We aimed to describe the patterns of BC presentation and to examine the differences in thedistribution of prognostic factors by gender, age, tumor size, and involvement region.Method: The patients diagnosed with BC (non-muscle invasive or muscle-invasive BC) were included. Intravesicaltreatment, tumor diameter, pathological grade, tumor involved area and tumor stage were recorded as variables. Thesurvival rates of the patients were calculated for diverse clinical and pathological findings.Results:In a total of 124 patients, 23 (18.5%) of patients were female and 101(81.5%) of patients were male, themedian age of all patients was 64 (IQR: 21-92). There were 36 % (41) patients in early-stage (stage 0 or stage insitu),50.9 % (58) patients in stage 1, 7% (8) patients in stage 2, 4.4 %(5) patients in stage 3 and 1.8% (2) patients were instage 4. There were significantly different OS rates of patients with BC in different stages (p2.5cm (group 2). There was asignificant difference between the overall survival rates of group 1 and group 2(p=0.02). There were 55 patients withlow-grade BC and 38 of patients with high-grade BC, and the difference between their survival rates was statisticallysignificant (p=0.001).Conclusions: Tumor stage, tumor diameter, and grade were demonstrated and confirmed as the crucial prognosticfactors of bladder cancer. Additionally, lateral walls of bladder constitute the most commonly involved area, but theirroles in the disease course still remain unclear.

Özet

Amaç: Mesane kanseri (MK), üriner sistemin en sık görülen malignitesidir ve görülme sıklığı bölgelere göre değişmektedir. Mesane kanseri erkeklerde kadınlardan daha yaygındır. Tümör evresi ve derecesi, MK'nin en önemli prognostik faktörleridir. Bu çalışmamızda mesane kanserinin klinik ve patolojik özelliklerini belirlemeyi, ayrıca bu özelliklerin prognostik değerleri ve hasta sağkalımı üzerine etkilerini incelemeyi amaçladık. Yöntemler: Çalışmaya mesane kanseri tanısı konan hastalar (kas tutulumu olmayan veya kas tutulumu olan) dahil edildi. Mesane içi tedavi tipi, tümör çapı, patolojik derece, tümörün oluştuğu bölge ve tümör evresi değişken olarak kaydedildi. Hastaların sağkalım oranları; tümör çapı, tümörün histopatolojik derecesi ve hastalığın evresi gibi çeşitli parametrelerle ilişkilendirildi. Bulgular: Toplam 124 hastanın 23'ü (%18,5) kadın, 101'i (%81,5) erkek, tüm hastaların ortalama yaşı 64 idi (21-92). Erken evrede %36 (41) hasta (evre 0 veya evre insitu), evre 1'de %50,9 (58) hasta, evre 2'de %7 (8), evre 3'te %4,4 (5) hasta ve evre 4’te %1,8'i (2) hasta saptandı. Evreler arası sağkalım oranları arasındaki fark istatistiksel olarak anlamlı idi (p

🔖

Cite This Article

SÖĞÜTÇÜ, N., LAKİN, Ş. (2022). The importance of clinical and pathological features in bladder cancer and its effects on disease course. Dicle Tıp Dergisi, Cilt: 46 - Sayı: 4, 821–829. https://ajindex.com/articles/487399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ploeg M, Aben KK, KiemeneyLA.The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289-293
  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108
  3. Jankovic S, Radosavljevic V. Risk factors for bladder cancer. Tumori. 2007; 93:4-12
  4. Hinotsu S, Akaza H, Miki T, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol. 2009;16:64-69
  5. Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. Urology. 2000;55:368-71
  6. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173-9
  7. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-77
  8. Cambier S, Sylvester RJ, Collette L, et al: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol. 2016;69:60-9
  9. Kirkali Z, Chan T, Manoharan M, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34
  10. Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young patients. J Urol. 1998;159:1493-6
  11. Jancke G, Rosell J, Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J UrolNephrol. 2011;45:388-92
  12. Amin MB, McKenney JK, Paner GP, et al: ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol. 2013;63:16-35
  13. Kim W, Song C, Park S,et al. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol. 2012;26:1059-64
  14. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: a cancer journal for clinicians. 2017;67:93-9.